The treatment of older AML patients is controversial. Older adults often cannot tolerate the toxicities of intensive remission induction chemotherapy. With the typical treatment plans, the treatment-related mortality is between 15% and 30%. Other less intensive regimens that may be used are oral agents (such as hydroxyurea), "low dose cytarabine" (20 mg/m 2 subcutaneous injection twice daily for 10 days), or one of the hypomethylating agents (azacitidine or decitabine). These are associated with less of a myelosuppressive effect, lower treatment-related mortality, and less time spent in the hospital.